Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
09 09 2021
Historique:
pubmed: 8 7 2021
medline: 12 10 2021
entrez: 7 7 2021
Statut: ppublish

Résumé

Modified vaccinia virus Ankara (MVA) was derived by repeated passaging in chick fibroblasts, during which deletions and mutations rendered the virus unable to replicate in most mammalian cells. Marker rescue experiments demonstrated that the host range defect could be overcome by replacing DNA that had been deleted from near the left end of the genome. One virus isolate, however, recovered the ability to replicate in monkey BS-C-1 cells but not human cells without added DNA, suggesting that it arose from a spontaneous mutation. Here, we showed that variants with enhanced ability to replicate in BS-C-1 cells could be isolated by blind passaging of MVA and that in each there was a point mutation leading to an amino acid substitution in the D10 decapping enzyme. The sufficiency of these single mutations to enhance host range was confirmed by constructing recombinant viruses. The D10 mutations occurred at N- or C-terminal locations distal to the active site, suggesting an indirect effect on decapping or on another previously unknown role of D10. Although increased amounts of viral mRNA and proteins were found in BS-C-1 cells infected with the mutants compared to those with parental MVA, the increases were much less than the 1- to 2-log-higher virus yields. Nevertheless, a contributing role for diminished decapping in overcoming the host range defect was consistent with increased replication and viral protein synthesis in BS-C-1 cells infected with an MVA engineered to have active-site mutations that abrogate decapping activity entirely. Optimal decapping may vary depending on the biological context.

Identifiants

pubmed: 34232734
doi: 10.1128/JVI.01104-21
pmc: PMC8428383
doi:

Substances chimiques

RNA, Messenger 0
RNA, Viral 0
Viral Proteins 0
D10 protein, vaccinia virus EC 3.1.3.-
Nucleotidases EC 3.1.3.-

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0110421

Subventions

Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID)

Références

Virology. 1997 Nov 24;238(2):198-211
pubmed: 9400593
J Virol. 1999 Jan;73(1):791-6
pubmed: 9847390
J Gen Virol. 1998 Feb;79 ( Pt 2):347-52
pubmed: 9472619
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9482-7
pubmed: 16769897
J Virol. 2016 Aug 12;90(17):7864-79
pubmed: 27334583
J Gen Virol. 1991 May;72 ( Pt 5):1031-8
pubmed: 2033387
Proc Natl Acad Sci U S A. 1970 Jul;66(3):677-84
pubmed: 5269234
J Virol. 2018 Sep 26;92(20):
pubmed: 30045995
J Virol. 2014 Jan;88(1):202-11
pubmed: 24155373
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2139-44
pubmed: 17283339
PLoS Pathog. 2019 May 30;15(5):e1007710
pubmed: 31145755
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3759-3767
pubmed: 32019881
J Virol. 2007 Dec;81(23):12973-8
pubmed: 17881455
Cell Host Microbe. 2015 Mar 11;17(3):320-331
pubmed: 25766293
J Virol. 2006 Jan;80(2):553-61
pubmed: 16378957
PLoS Pathog. 2020 Oct 8;16(10):e1008926
pubmed: 33031446
J Mol Biol. 1973 Dec 5;81(2):267-9
pubmed: 4777308
Virology. 1998 May 10;244(2):365-96
pubmed: 9601507
J Virol. 2020 Aug 31;94(18):
pubmed: 32669330
Virology. 1998 Nov 25;251(2):334-42
pubmed: 9837798
J Virol. 2018 Nov 12;92(23):
pubmed: 30209174

Auteurs

Noam Erez (N)

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.

Linda S Wyatt (LS)

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.

Jeffrey L Americo (JL)

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.

Wei Xiao (W)

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.

Bernard Moss (B)

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH